Phase 2 N=18 A Study of Modified Stem Cells in Stable Ischemic Stroke
Chronic Ischemic Stroke
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=49 The Efficacy of Normobaric Oxygen on Chronic Cerebral Ischemia
Normobaric Oxygen · Cerebral Ischemia
Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio
N/A N=23 Treatment of Chronic Stroke With IpsiHand
Stroke
Primary: Change in Action Research Arm Test (ARAT) Score — 6.2 units on a scale — p=0.002
N/A N=31 Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke
Stroke
Primary: Changes in Brain Activation — 48.5; -30 voxels
Phase 2 N=163 Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Chronic Ischemic Stroke
Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743
N/A N=12,551 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
Stroke
Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=20 Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke
Stroke
Primary: Change in Corticomotor Excitability — 0.38; 0.37; 0.41; 0.37 millivolt (mV)
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
N/A N=1,500 Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)
Stroke, Acute · Ischemic Stroke · Hemorrhagic Stroke
Primary: Modified Rankin Scale at 3 Months in Acute Stroke (AIS and ICH) — 2; 1 units on a scale
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
Phase 2 N=83 A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke
Ischemic Stroke
Primary: Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs) — 30…
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
N/A N=147,716 Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke
Ischemic Stroke
Primary: Number of Participants Receiving Inpatient, Home, or Community Based Rehabilitation Services — 76720; 32350 participants
Phase 4 N=777 ISCHEMIA-Chronic Kidney Disease Trial
Cardiovascular Diseases · Coronary Artery Disease · Heart Diseases
Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
Phase 4 N=80 Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients
Stroke, Acute
Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml
Phase 2 N=103 The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
Cerebrovascular Disease
Primary: Blood Pressure and Heart Rates;
Phase 2 N=79 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
Stroke · Stroke, Acute · Brain Injury, Acute
Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71
Phase 3 N=318 Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
Chronic Cerebral Ischemia
Primary: Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in Comparison With Reference Score at Visit 0 — 25.72; 23.95; 4.22; 2.17 score on a scale
Phase 2 N=40 Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
Ischemic Stroke
Primary: Technical Device Success by as Assessed by the Percentage of Participants Which Established at Least TIMI 2 Flow Upon Deployment of the System Across the Occlusion and…
N/A N=42,188 Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
Stroke
Primary: Percentage of Patients Who Received Intravenous Recombinant Plasminogen Activator (IV-rtPA) Treatment Within 3 Hours of Symptom Onset Among 2 Hours Intravenous…
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants